Richard Mulligan has sold SANA and made no open-market buys since Sep 2024

Richard Mulligan, Ph.D. is an individual and a biotechnology executive, scientist, and board member at Sana Biotechnology, Inc. He has served as the company’s Head of SanaX and Executive Vice Chairman of the Board since November 2018, and Sana’s materials also note that he previously served as a consultant and later in several employee roles, most recently as Head of Sana Innovation Research until March 2024.(

Before joining Sana, Dr. Mulligan was the Mallinckrodt Professor of Genetics, Emeritus, at Harvard Medical School and directed the Harvard Gene Therapy Initiative from 1996 to 2013; he also held faculty appointments at MIT and was a member of the Whitehead Institute for Biomedical Research.( He later worked in investment management as Founding Partner and Senior Managing Director of Sarissa Capital Management and as Portfolio Manager at Icahn Capital LP. Dr. Mulligan serves on the boards of Biogen Inc. and Bausch Health Companies Inc., earned his B.S. from MIT and Ph.D. in Biochemistry from Stanford University School of Medicine, and has received honors including the MacArthur Foundation Genius Prize.(

Written by Perplexity from public sources.